IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Relapsing-remitting Multiple Sclerosis
Rennes University Hospitalmonoclonal_antibodyPhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 89/ 100
Competitive context
79 Active assets in the Relapsing-remitting Multiple Sclerosis cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Fingolimod TG Therapeutics, Inc. | Phase 4 | A |
Natalizumab Biogen | Phase 4 | BBB |
Glatiramer University Hospital, Montpellier | Phase 4 | BBB |
Interferon ?1 (human fibroblast protein moiety) Biogen | Phase 4 | BBB |
2-BUTENEDIOIC ACID, (2E)-, DIMETHYL ESTER University Hospital, Montpellier | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →